D*阶段研究:在一项随机对照非劣效性试验中,比较短期心理动力学心理疗法和认知行为疗法对重度抑郁症的治疗效果。

IF 4.9 2区 医学 Q1 CLINICAL NEUROLOGY
Journal of affective disorders Pub Date : 2025-02-15 Epub Date: 2024-10-30 DOI:10.1016/j.jad.2024.10.122
Maartje Miggiels, Peter Ten Klooster, Aartjan Beekman, Susanne Bremer, Jack Dekker, Colin Janssen, Maarten K van Dijk
{"title":"D*阶段研究:在一项随机对照非劣效性试验中,比较短期心理动力学心理疗法和认知行为疗法对重度抑郁症的治疗效果。","authors":"Maartje Miggiels, Peter Ten Klooster, Aartjan Beekman, Susanne Bremer, Jack Dekker, Colin Janssen, Maarten K van Dijk","doi":"10.1016/j.jad.2024.10.122","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Given both the large volume and manifold preferences of patients with depression, the availability of various effective treatments is important. Psychodynamic psychotherapy (PDT) has received less research in comparison to cognitive behavioural therapy (CBT) for major depressive disorder (MDD). This study aimed to establish whether short-term psychodynamic supportive psychotherapy (SPSP) is non-inferior to CBT in the treatment of MDD.</p><p><strong>Methods: </strong>A non-inferiority trial was conducted in a Dutch mental health setting, with 290 patients randomised to receive 16 sessions of either CBT or SPSP, over eight weeks. Primary outcome was depressive symptom severity assessed using the self-rated Inventory of Depressive Symptomatology (IDS-SR). The non-inferiority margin was prespecified as a - 5 post-treatment difference on the IDS-SR. Secondary outcome measures were functional impairment caused by symptoms assessed using the Sheehan disability scale (SDS), and wellbeing measured by the Mental Health Continuum-Short Form (MHC-SF).</p><p><strong>Results: </strong>Both intention-to-treat (baseline-adjusted mean difference 1.62, 95 % CI -1.82 to 5.05) and per-protocol analyses (mean difference 2.54; 95 % CI -0.63 to 5.72) showed SPSP to be non-inferior to CBT in reducing depressive symptoms. SPSP showed slightly but significantly higher remission rates and wellbeing scores.</p><p><strong>Limitations: </strong>Patients opting for other therapies or medication did not take part in the trial. Follow-up measures or clinician-rated questionnaires were not included.</p><p><strong>Conclusions: </strong>The findings support SPSP as a viable treatment option for MDD, expanding the available choices for patients and broadening treatment options.</p>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":" ","pages":"344-351"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The D*Phase-study: Comparing short-term psychodynamic psychotherapy and cognitive behavioural therapy for major depressive disorder in a randomised controlled non-inferiority trial.\",\"authors\":\"Maartje Miggiels, Peter Ten Klooster, Aartjan Beekman, Susanne Bremer, Jack Dekker, Colin Janssen, Maarten K van Dijk\",\"doi\":\"10.1016/j.jad.2024.10.122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Given both the large volume and manifold preferences of patients with depression, the availability of various effective treatments is important. Psychodynamic psychotherapy (PDT) has received less research in comparison to cognitive behavioural therapy (CBT) for major depressive disorder (MDD). This study aimed to establish whether short-term psychodynamic supportive psychotherapy (SPSP) is non-inferior to CBT in the treatment of MDD.</p><p><strong>Methods: </strong>A non-inferiority trial was conducted in a Dutch mental health setting, with 290 patients randomised to receive 16 sessions of either CBT or SPSP, over eight weeks. Primary outcome was depressive symptom severity assessed using the self-rated Inventory of Depressive Symptomatology (IDS-SR). The non-inferiority margin was prespecified as a - 5 post-treatment difference on the IDS-SR. Secondary outcome measures were functional impairment caused by symptoms assessed using the Sheehan disability scale (SDS), and wellbeing measured by the Mental Health Continuum-Short Form (MHC-SF).</p><p><strong>Results: </strong>Both intention-to-treat (baseline-adjusted mean difference 1.62, 95 % CI -1.82 to 5.05) and per-protocol analyses (mean difference 2.54; 95 % CI -0.63 to 5.72) showed SPSP to be non-inferior to CBT in reducing depressive symptoms. SPSP showed slightly but significantly higher remission rates and wellbeing scores.</p><p><strong>Limitations: </strong>Patients opting for other therapies or medication did not take part in the trial. Follow-up measures or clinician-rated questionnaires were not included.</p><p><strong>Conclusions: </strong>The findings support SPSP as a viable treatment option for MDD, expanding the available choices for patients and broadening treatment options.</p>\",\"PeriodicalId\":14963,\"journal\":{\"name\":\"Journal of affective disorders\",\"volume\":\" \",\"pages\":\"344-351\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of affective disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jad.2024.10.122\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jad.2024.10.122","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:鉴于抑郁症患者人数众多且偏好各异,提供各种有效的治疗方法非常重要。与认知行为疗法(CBT)相比,心理动力学心理疗法(PDT)对重度抑郁障碍(MDD)的研究较少。本研究旨在确定短期心理动力学支持性心理疗法(SPSP)在治疗重度抑郁障碍方面是否不逊于 CBT:方法:在荷兰的一家精神卫生机构进行了一项非劣效性试验,290 名患者被随机分配接受为期 8 周、共 16 次的 CBT 或 SPSP 治疗。主要结果是使用抑郁症状自评量表(IDS-SR)评估抑郁症状的严重程度。预设的非劣效差为治疗后 IDS-SR 差异为-5。次要结果测量指标是由症状引起的功能障碍,使用希恩残疾量表(SDS)进行评估,以及由心理健康连续短表(MHC-SF)测量的幸福感:意向治疗(基线调整后的平均差异为 1.62,95 % CI -1.82 至 5.05)和按协议分析(平均差异为 2.54;95 % CI -0.63 至 5.72)均显示,在减少抑郁症状方面,SPSP 的效果不劣于 CBT。SPSP的缓解率和健康评分略高,但明显更高:选择其他疗法或药物治疗的患者未参与试验。结论:研究结果表明,SPSP 是治疗 MDD 的一种可行方法,它扩大了患者的选择范围,拓宽了治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The D*Phase-study: Comparing short-term psychodynamic psychotherapy and cognitive behavioural therapy for major depressive disorder in a randomised controlled non-inferiority trial.

Background: Given both the large volume and manifold preferences of patients with depression, the availability of various effective treatments is important. Psychodynamic psychotherapy (PDT) has received less research in comparison to cognitive behavioural therapy (CBT) for major depressive disorder (MDD). This study aimed to establish whether short-term psychodynamic supportive psychotherapy (SPSP) is non-inferior to CBT in the treatment of MDD.

Methods: A non-inferiority trial was conducted in a Dutch mental health setting, with 290 patients randomised to receive 16 sessions of either CBT or SPSP, over eight weeks. Primary outcome was depressive symptom severity assessed using the self-rated Inventory of Depressive Symptomatology (IDS-SR). The non-inferiority margin was prespecified as a - 5 post-treatment difference on the IDS-SR. Secondary outcome measures were functional impairment caused by symptoms assessed using the Sheehan disability scale (SDS), and wellbeing measured by the Mental Health Continuum-Short Form (MHC-SF).

Results: Both intention-to-treat (baseline-adjusted mean difference 1.62, 95 % CI -1.82 to 5.05) and per-protocol analyses (mean difference 2.54; 95 % CI -0.63 to 5.72) showed SPSP to be non-inferior to CBT in reducing depressive symptoms. SPSP showed slightly but significantly higher remission rates and wellbeing scores.

Limitations: Patients opting for other therapies or medication did not take part in the trial. Follow-up measures or clinician-rated questionnaires were not included.

Conclusions: The findings support SPSP as a viable treatment option for MDD, expanding the available choices for patients and broadening treatment options.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of affective disorders
Journal of affective disorders 医学-精神病学
CiteScore
10.90
自引率
6.10%
发文量
1319
审稿时长
9.3 weeks
期刊介绍: The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信